{"id": "article-28102_0", "title": "Pyoderma Gangrenosum -- Continuing Education Activity", "content": "Pyoderma gangrenosum is an ulcerative disorder that falls into the category of neutrophilic dermatoses. Pyoderma gangrenosum should not be confused with pyogenic granuloma, a completely separate entity but with an equally ill-fitting name. Despite its name, pyoderma gangrenosum is not caused by infection or gangrene. Pyogenic granuloma is often associated with systemic disease. The diagnosis is made clinically after excluding other similar skin disorders. This activity reviews the pathophysiology of pyoderma gangrenosum and stresses the importance of the interprofessional team in its management.", "contents": "Pyoderma Gangrenosum -- Continuing Education Activity. Pyoderma gangrenosum is an ulcerative disorder that falls into the category of neutrophilic dermatoses. Pyoderma gangrenosum should not be confused with pyogenic granuloma, a completely separate entity but with an equally ill-fitting name. Despite its name, pyoderma gangrenosum is not caused by infection or gangrene. Pyogenic granuloma is often associated with systemic disease. The diagnosis is made clinically after excluding other similar skin disorders. This activity reviews the pathophysiology of pyoderma gangrenosum and stresses the importance of the interprofessional team in its management."}
{"id": "article-28102_1", "title": "Pyoderma Gangrenosum -- Continuing Education Activity", "content": "Objectives: Review the etiology of pyoderma gangrenosum. Describe the pathophysiology of pyoderma gangrenosum. Summarize the treatment options for pyoderma gangrenosum. Explain the importance of improving care coordination among interprofessional team members to improve outcomes for patients affected by pyoderma gangrenosum. Access free multiple choice questions on this topic.", "contents": "Pyoderma Gangrenosum -- Continuing Education Activity. Objectives: Review the etiology of pyoderma gangrenosum. Describe the pathophysiology of pyoderma gangrenosum. Summarize the treatment options for pyoderma gangrenosum. Explain the importance of improving care coordination among interprofessional team members to improve outcomes for patients affected by pyoderma gangrenosum. Access free multiple choice questions on this topic."}
{"id": "article-28102_2", "title": "Pyoderma Gangrenosum -- Introduction", "content": "Pyoderma gangrenosum is an ulcerative disorder that falls into the category of neutrophilic dermatoses. Pyoderma gangrenosum should not be confused with pyogenic granuloma, a completely\u00a0separate entity but with an equally ill-fitting name. Despite its name, pyoderma gangrenosum is not caused by infection or gangrene. Pyogenic granuloma is often associated with systemic disease.\u00a0 The diagnosis is made clinically after excluding other similar skin disorders. [1] [2] [3]", "contents": "Pyoderma Gangrenosum -- Introduction. Pyoderma gangrenosum is an ulcerative disorder that falls into the category of neutrophilic dermatoses. Pyoderma gangrenosum should not be confused with pyogenic granuloma, a completely\u00a0separate entity but with an equally ill-fitting name. Despite its name, pyoderma gangrenosum is not caused by infection or gangrene. Pyogenic granuloma is often associated with systemic disease.\u00a0 The diagnosis is made clinically after excluding other similar skin disorders. [1] [2] [3]"}
{"id": "article-28102_3", "title": "Pyoderma Gangrenosum -- Etiology", "content": "The most common associated systemic disorders include rheumatoid arthritis, inflammatory bowel disease, and other autoimmune and inflammatory conditions. In addition, pyoderma gangrenosum has an association with both solid tumors and hematologic malignancies. Pyoderma gangrenosum is associated with ulcerative colitis in 5% to 12% of cases and is associated with Crohn disease in 1% to\u00a02% of cases. It is not clear if the development of pyoderma gangrenosum correlates with severity or flares of inflammatory bowel disease. Furthermore, pyoderma gangrenosum does not always resolve when the associated bowel disease is treated. In a study of 103 patients with pyoderma gangrenosum, 20% of the patients had hematologic disorders, and 19% of the patients had seronegative arthritis. [4] [5] [6]", "contents": "Pyoderma Gangrenosum -- Etiology. The most common associated systemic disorders include rheumatoid arthritis, inflammatory bowel disease, and other autoimmune and inflammatory conditions. In addition, pyoderma gangrenosum has an association with both solid tumors and hematologic malignancies. Pyoderma gangrenosum is associated with ulcerative colitis in 5% to 12% of cases and is associated with Crohn disease in 1% to\u00a02% of cases. It is not clear if the development of pyoderma gangrenosum correlates with severity or flares of inflammatory bowel disease. Furthermore, pyoderma gangrenosum does not always resolve when the associated bowel disease is treated. In a study of 103 patients with pyoderma gangrenosum, 20% of the patients had hematologic disorders, and 19% of the patients had seronegative arthritis. [4] [5] [6]"}
{"id": "article-28102_4", "title": "Pyoderma Gangrenosum -- Epidemiology", "content": "It is estimated that less than 5% of cases occur in children. The age range for the development of the disease is from about 11 to 89 years of age.", "contents": "Pyoderma Gangrenosum -- Epidemiology. It is estimated that less than 5% of cases occur in children. The age range for the development of the disease is from about 11 to 89 years of age."}
{"id": "article-28102_5", "title": "Pyoderma Gangrenosum -- Pathophysiology", "content": "The pathogenesis of pyoderma gangrenosum is not fully understood. It is thought to involve genetic mutations, neutrophil dysfunction, and immune/inflammatory dysregulation. Some lesions of pyoderma gangrenosum have been found to have a proliferation of clonal T-cells. In addition, inflammasomes have been postulated to be involved in the neutrophil chemotaxis that occurs in these lesions. Inflammasomes are complexes of receptors that are\u00a0part of innate immune system signaling. Some cases of pyoderma gangrenosum are associated with a mutation in Janus kinase 2 , which is involved in the production of several cytokines. Abnormal cytokine signaling by T cells and macrophages is likely a component of the disease process. Lesions of pyoderma gangrenosum have been found to have increased levels of inflammatory mediators. For example, IL-23 has been found to be increased in lesions of pyoderma gangrenosum. IL-23 is important in activating neutrophils and stimulating IL-17 mediated inflammation. [7]", "contents": "Pyoderma Gangrenosum -- Pathophysiology. The pathogenesis of pyoderma gangrenosum is not fully understood. It is thought to involve genetic mutations, neutrophil dysfunction, and immune/inflammatory dysregulation. Some lesions of pyoderma gangrenosum have been found to have a proliferation of clonal T-cells. In addition, inflammasomes have been postulated to be involved in the neutrophil chemotaxis that occurs in these lesions. Inflammasomes are complexes of receptors that are\u00a0part of innate immune system signaling. Some cases of pyoderma gangrenosum are associated with a mutation in Janus kinase 2 , which is involved in the production of several cytokines. Abnormal cytokine signaling by T cells and macrophages is likely a component of the disease process. Lesions of pyoderma gangrenosum have been found to have increased levels of inflammatory mediators. For example, IL-23 has been found to be increased in lesions of pyoderma gangrenosum. IL-23 is important in activating neutrophils and stimulating IL-17 mediated inflammation. [7]"}
{"id": "article-28102_6", "title": "Pyoderma Gangrenosum -- Histopathology", "content": "The disease is a clinical and histologic diagnosis of exclusion as the histologic features are non-specific. The goal of the biopsy is to exclude other causes of ulceration. Early lesions of pyoderma gangrenosum should show an infiltrate of neutrophils in the dermis. Lesions may demonstrate necrotic dermal vessels. Direct immunofluorescence of biopsy specimens of pyoderma gangrenosum is nonspecific.", "contents": "Pyoderma Gangrenosum -- Histopathology. The disease is a clinical and histologic diagnosis of exclusion as the histologic features are non-specific. The goal of the biopsy is to exclude other causes of ulceration. Early lesions of pyoderma gangrenosum should show an infiltrate of neutrophils in the dermis. Lesions may demonstrate necrotic dermal vessels. Direct immunofluorescence of biopsy specimens of pyoderma gangrenosum is nonspecific."}
{"id": "article-28102_7", "title": "Pyoderma Gangrenosum -- History and Physical", "content": "Some of the clinical variants of pyoderma gangrenosum include vesicular-bullous, pustular, ulcerative, and superficial granulomatous forms. The vesicular-bullous variant appears on the upper extremities and face and has overlap with another neutrophilic disorder, Sweet syndrome. There can be systemic symptoms including fever and joint pain. The pustular type of\u00a0pyoderma gangrenosum features many small pustules. These pustules may either resolve or develop into ulcers. This variant is associated with inflammatory bowel disease. In addition to these variants, pyoderma gangrenosum can present as a vegetative form. Certain, less common, sites of involvement, such as the vulva and peristomal area, can be very\u00a0resistant to treatment. Patients often experience pain associated with the lesions that may be out of proportion to the size of the ulcer. Lesions of pyoderma gangrenosum usually heal with a cribriform scar.", "contents": "Pyoderma Gangrenosum -- History and Physical. Some of the clinical variants of pyoderma gangrenosum include vesicular-bullous, pustular, ulcerative, and superficial granulomatous forms. The vesicular-bullous variant appears on the upper extremities and face and has overlap with another neutrophilic disorder, Sweet syndrome. There can be systemic symptoms including fever and joint pain. The pustular type of\u00a0pyoderma gangrenosum features many small pustules. These pustules may either resolve or develop into ulcers. This variant is associated with inflammatory bowel disease. In addition to these variants, pyoderma gangrenosum can present as a vegetative form. Certain, less common, sites of involvement, such as the vulva and peristomal area, can be very\u00a0resistant to treatment. Patients often experience pain associated with the lesions that may be out of proportion to the size of the ulcer. Lesions of pyoderma gangrenosum usually heal with a cribriform scar."}
{"id": "article-28102_8", "title": "Pyoderma Gangrenosum -- History and Physical", "content": "One of the most important features of the disease is a phenomenon known as pathergy. Pathergy is defined as an exaggerated response to a minor skin injury or worsening of an existing wound with minimal insult or trauma. This has a wide array of implications for the patient including debridement and simple wound care. This also makes the decision to perform certain surgeries and procedures much more difficult. Lastly, insults to the skin that would be nearly meaningless for most people can be devastating for some patients with pyoderma gangrenosum.", "contents": "Pyoderma Gangrenosum -- History and Physical. One of the most important features of the disease is a phenomenon known as pathergy. Pathergy is defined as an exaggerated response to a minor skin injury or worsening of an existing wound with minimal insult or trauma. This has a wide array of implications for the patient including debridement and simple wound care. This also makes the decision to perform certain surgeries and procedures much more difficult. Lastly, insults to the skin that would be nearly meaningless for most people can be devastating for some patients with pyoderma gangrenosum."}
{"id": "article-28102_9", "title": "Pyoderma Gangrenosum -- Evaluation", "content": "As mentioned, pyoderma gangrenosum is a diagnosis of exclusion both clinically and histologically. In addition to nonspecific histologic features, there are no specific lab markers that aid in its diagnosis. [8] [9] [10] In 2004, diagnostic criteria were proposed but have not been confirmed. According to this proposal, both major criteria and two of the minor criteria are required to make the diagnosis.", "contents": "Pyoderma Gangrenosum -- Evaluation. As mentioned, pyoderma gangrenosum is a diagnosis of exclusion both clinically and histologically. In addition to nonspecific histologic features, there are no specific lab markers that aid in its diagnosis. [8] [9] [10] In 2004, diagnostic criteria were proposed but have not been confirmed. According to this proposal, both major criteria and two of the minor criteria are required to make the diagnosis."}
{"id": "article-28102_10", "title": "Pyoderma Gangrenosum -- Evaluation -- Major Criteria", "content": "Rapid progression of a painful, necrolytic cutaneous ulcer with an irregular, violaceous, and undermined border Other causes of cutaneous ulceration have been excluded", "contents": "Pyoderma Gangrenosum -- Evaluation -- Major Criteria. Rapid progression of a painful, necrolytic cutaneous ulcer with an irregular, violaceous, and undermined border Other causes of cutaneous ulceration have been excluded"}
{"id": "article-28102_11", "title": "Pyoderma Gangrenosum -- Evaluation -- Minor Criteria", "content": "History suggestive of pathergy or cribriform scarring Systemic diseases associated with pyoderma gangrenosum Histopathologic findings (sterile dermal neutrophilia, +/- mixed inflammation,\u00a0\u00a0+/-\u00a0\u00a0lymphocytic vasculitis) Treatment response (rapid response to systemic steroid treatment)", "contents": "Pyoderma Gangrenosum -- Evaluation -- Minor Criteria. History suggestive of pathergy or cribriform scarring Systemic diseases associated with pyoderma gangrenosum Histopathologic findings (sterile dermal neutrophilia, +/- mixed inflammation,\u00a0\u00a0+/-\u00a0\u00a0lymphocytic vasculitis) Treatment response (rapid response to systemic steroid treatment)"}
{"id": "article-28102_12", "title": "Pyoderma Gangrenosum -- Evaluation", "content": "A number of syndromes include pyoderma gangrenosum in the clinical criteria and are named with acronyms for these criteria. These include syndromes like PAPA syndrome which includes pyoderma gangrenosum, acne, and pyogenic sterile arthritis and PASH syndrome which includes pyoderma gangrenosum, acne, and hidradenitis suppurativa. A helpful way to organize these disorders is by remembering that\u00a0they all include pyoderma gangrenosum and acne but are distinguished by the addition of hidradenitis suppurativa, colitis, and certain types of arthritis. These disorders share the common factor of immune system dysregulation with aberrant interleukin-1 signaling. The pathergy skin test involves poking the skin and observing for an exaggerated reaction.", "contents": "Pyoderma Gangrenosum -- Evaluation. A number of syndromes include pyoderma gangrenosum in the clinical criteria and are named with acronyms for these criteria. These include syndromes like PAPA syndrome which includes pyoderma gangrenosum, acne, and pyogenic sterile arthritis and PASH syndrome which includes pyoderma gangrenosum, acne, and hidradenitis suppurativa. A helpful way to organize these disorders is by remembering that\u00a0they all include pyoderma gangrenosum and acne but are distinguished by the addition of hidradenitis suppurativa, colitis, and certain types of arthritis. These disorders share the common factor of immune system dysregulation with aberrant interleukin-1 signaling. The pathergy skin test involves poking the skin and observing for an exaggerated reaction."}
{"id": "article-28102_13", "title": "Pyoderma Gangrenosum -- Treatment / Management", "content": "If present, the underlying systemic disease must be treated, but there is not an accepted correlation between the underlying systemic disease severity and the severity of pyoderma gangrenosum. [11] [2]", "contents": "Pyoderma Gangrenosum -- Treatment / Management. If present, the underlying systemic disease must be treated, but there is not an accepted correlation between the underlying systemic disease severity and the severity of pyoderma gangrenosum. [11] [2]"}
{"id": "article-28102_14", "title": "Pyoderma Gangrenosum -- Treatment / Management", "content": "The use of systemic immunosuppression is determined by how fast the disease progresses. If the size of the\u00a0lesion is rapidly growing, systemic medications like corticosteroids or cyclosporine may be used. The STOP GAP randomized control trial in 2015 compared oral prednisolone and oral cyclosporine in the treatment of pyoderma gangrenosum. The results did not show a significant difference in the speed of lesion healing with either medication. At six months, 47% of patients on cyclosporine had healed ulcers,\u00a0and 47% of the patients on prednisolone had healed ulcers. Recurrence was similar among the two groups as were adverse reactions. However, serious adverse reactions such as infections were more common in the patients receiving prednisolone.", "contents": "Pyoderma Gangrenosum -- Treatment / Management. The use of systemic immunosuppression is determined by how fast the disease progresses. If the size of the\u00a0lesion is rapidly growing, systemic medications like corticosteroids or cyclosporine may be used. The STOP GAP randomized control trial in 2015 compared oral prednisolone and oral cyclosporine in the treatment of pyoderma gangrenosum. The results did not show a significant difference in the speed of lesion healing with either medication. At six months, 47% of patients on cyclosporine had healed ulcers,\u00a0and 47% of the patients on prednisolone had healed ulcers. Recurrence was similar among the two groups as were adverse reactions. However, serious adverse reactions such as infections were more common in the patients receiving prednisolone."}
{"id": "article-28102_15", "title": "Pyoderma Gangrenosum -- Treatment / Management", "content": "If a patient has a history of pyoderma gangrenosum, especially aggressive pyoderma gangrenosum, some physicians will use immunosuppressant drugs prophylactically before surgery to prevent the formation of pyoderma gangrenosum. One such regimen consists of methylprednisolone and cyclosporine combined. Obviously, avoiding unnecessary surgery or procedures is essential. [12]", "contents": "Pyoderma Gangrenosum -- Treatment / Management. If a patient has a history of pyoderma gangrenosum, especially aggressive pyoderma gangrenosum, some physicians will use immunosuppressant drugs prophylactically before surgery to prevent the formation of pyoderma gangrenosum. One such regimen consists of methylprednisolone and cyclosporine combined. Obviously, avoiding unnecessary surgery or procedures is essential. [12]"}
{"id": "article-28102_16", "title": "Pyoderma Gangrenosum -- Treatment / Management", "content": "For more indolent or limited disease, topical or intralesional therapy alone may be sufficient. Topical and intralesional steroids, as well as topical tacrolimus, have been used with success. Other agents that have been tried are nicotine, topical dapsone, and sodium cromoglycate.", "contents": "Pyoderma Gangrenosum -- Treatment / Management. For more indolent or limited disease, topical or intralesional therapy alone may be sufficient. Topical and intralesional steroids, as well as topical tacrolimus, have been used with success. Other agents that have been tried are nicotine, topical dapsone, and sodium cromoglycate."}
{"id": "article-28102_17", "title": "Pyoderma Gangrenosum -- Treatment / Management", "content": "Wound care and pain control are key features in the treatment of pyoderma gangrenosum. Patients and healthcare providers must cleanse the wound to prevent infection. Debridement is important but must be performed very\u00a0cautiously to ensure that only nonviable tissue is removed because of the aforementioned association with pathergy.", "contents": "Pyoderma Gangrenosum -- Treatment / Management. Wound care and pain control are key features in the treatment of pyoderma gangrenosum. Patients and healthcare providers must cleanse the wound to prevent infection. Debridement is important but must be performed very\u00a0cautiously to ensure that only nonviable tissue is removed because of the aforementioned association with pathergy."}
{"id": "article-28102_18", "title": "Pyoderma Gangrenosum -- Treatment / Management", "content": "Other therapies that have been successful are anti-TNF-alpha drugs such as etanercept and adalimumab. Ustekinumab, an IL-12/23 inhibitor used in the treatment of psoriasis, has been reported to improve pyoderma gangrenosum. Other therapies that may be effective in the treatment of pyoderma gangrenosum include Canakinumab, an IL-1 beta monoclonal antibody,\u00a0and tocilizumab, an anti IL-6 monoclonal antibody.", "contents": "Pyoderma Gangrenosum -- Treatment / Management. Other therapies that have been successful are anti-TNF-alpha drugs such as etanercept and adalimumab. Ustekinumab, an IL-12/23 inhibitor used in the treatment of psoriasis, has been reported to improve pyoderma gangrenosum. Other therapies that may be effective in the treatment of pyoderma gangrenosum include Canakinumab, an IL-1 beta monoclonal antibody,\u00a0and tocilizumab, an anti IL-6 monoclonal antibody."}
{"id": "article-28102_19", "title": "Pyoderma Gangrenosum -- Differential Diagnosis", "content": "The differential diagnosis includes infectious diseases like mycobacterial infection and deep fungal infections. Also included in the differential are noninfectious diseases such as iododerma or bromoderma. Other causes of ulcers to\u00a0consider are arterial ulcers and Martorell ulcers. Arterial ulcers may have associated weakened pulses on the corresponding anatomical side.", "contents": "Pyoderma Gangrenosum -- Differential Diagnosis. The differential diagnosis includes infectious diseases like mycobacterial infection and deep fungal infections. Also included in the differential are noninfectious diseases such as iododerma or bromoderma. Other causes of ulcers to\u00a0consider are arterial ulcers and Martorell ulcers. Arterial ulcers may have associated weakened pulses on the corresponding anatomical side."}
{"id": "article-28102_20", "title": "Pyoderma Gangrenosum -- Enhancing Healthcare Team Outcomes", "content": "The treatment of pyoderma gangrenosum requires an interprofessional approach. The skin lesions take a long time to heal, frequently breakdown despite adequate treatment and are very painful.\u00a0Besides the physician, a wound care nurse is necessary. The wound care nurse has to educate the patient on adequate wound management, avoidance of trauma and also maintain physical activity. The pharmacist should encourage the patient to avoid smoking and be compliant with the medications, as relapses are common.\u00a0 Because the pain is often severe, prescription-strength opioids are\u00a0often required but these drugs should be tapered quickly to avoid physical dependence. A pain\u00a0consultation should be made\u00a0to help manage the pain without opioids. All patients should be told to avoid surgery as this often results in poor wound healing and development of pathergy. [13] [14] [Level\u00a05] An interprofessional approach as outlined here is the best means of achieving positive patient outcomes. [Level 5] Outcomes", "contents": "Pyoderma Gangrenosum -- Enhancing Healthcare Team Outcomes. The treatment of pyoderma gangrenosum requires an interprofessional approach. The skin lesions take a long time to heal, frequently breakdown despite adequate treatment and are very painful.\u00a0Besides the physician, a wound care nurse is necessary. The wound care nurse has to educate the patient on adequate wound management, avoidance of trauma and also maintain physical activity. The pharmacist should encourage the patient to avoid smoking and be compliant with the medications, as relapses are common.\u00a0 Because the pain is often severe, prescription-strength opioids are\u00a0often required but these drugs should be tapered quickly to avoid physical dependence. A pain\u00a0consultation should be made\u00a0to help manage the pain without opioids. All patients should be told to avoid surgery as this often results in poor wound healing and development of pathergy. [13] [14] [Level\u00a05] An interprofessional approach as outlined here is the best means of achieving positive patient outcomes. [Level 5] Outcomes"}
{"id": "article-28102_21", "title": "Pyoderma Gangrenosum -- Enhancing Healthcare Team Outcomes", "content": "In the majority of patients, the prognosis is good but the skin disorder does recur. In addition, most people\u00a0are left some\u00a0residual scar. The acute disorder is also associated with moderate-to-severe pain that often requires prescription-strength opioids. Despite the use of immunosuppressive agents, relapses are common and long-term care is required. The skin lesions breakdown from minimal trauma. [15] [16] (level V)", "contents": "Pyoderma Gangrenosum -- Enhancing Healthcare Team Outcomes. In the majority of patients, the prognosis is good but the skin disorder does recur. In addition, most people\u00a0are left some\u00a0residual scar. The acute disorder is also associated with moderate-to-severe pain that often requires prescription-strength opioids. Despite the use of immunosuppressive agents, relapses are common and long-term care is required. The skin lesions breakdown from minimal trauma. [15] [16] (level V)"}
{"id": "article-28102_22", "title": "Pyoderma Gangrenosum -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Pyoderma Gangrenosum -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}